Liposome-based co-delivery of siRNA and docetaxel for the synergistic treatment of lung cancer

International Journal of Pharmaceutics

Volumn 474, Issue 1-2, 2014, Pages 112-122

  Qu, Mei Hua ^a   Zeng, Rui Fang ^b   Fang, Shi ^b   Dai, Qiang Sheng ^b   Li, He Ping ^b   Long, Jian Ting ^b  

^a Third People's Hospital of Dalian   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

Antitumor; Docetaxel; Liposomes; Lung cancer; siRNA

Indexed keywords

CASPASE 3; CASPASE 7; DOCETAXEL; LIPOSOME; MESSENGER RNA; PROTEIN BCL 2; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; TAXOID;

ANIMAL EXPERIMENT; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; DRUG POTENTIATION; IN VIVO STUDY; LUNG CANCER; MOUSE; NONHUMAN; PARTICLE SIZE; PRIORITY JOURNAL; RAT; SUSTAINED DRUG RELEASE; TUMOR XENOGRAFT; ZETA POTENTIAL; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; DOSE RESPONSE; DRUG EFFECTS; DRUG SCREENING; HUMAN; LUNG NEOPLASMS; NEOPLASMS, EXPERIMENTAL; NUDE MOUSE; PATHOLOGY; SPRAGUE DAWLEY RAT; STRUCTURE ACTIVITY RELATION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; DRUG SYNERGISM; HUMANS; LIPOSOMES; LUNG NEOPLASMS; MICE; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; RATS; RATS, SPRAGUE-DAWLEY; RNA, SMALL INTERFERING; STRUCTURE-ACTIVITY RELATIONSHIP; TAXOIDS;

EID: 84906691847     PISSN: 03785173     EISSN: 18733476     Source Type: Journal    
DOI: 10.1016/j.ijpharm.2014.08.019     Document Type: Article

References (30)

1. L. Aagaard, and J.J. Rossi RNAi therapeutics: principles, prospects and challenges Adv. Drug Del. Rev. 59 2007 75 86 (Pubitemid 46770900)
2. W. Berger, U. Setinek, P. Hollaus, T. Zidek, E. Steiner, L. Elbling, H. Cantonati, J. Attems, A. Gsur, and M. Micksche Multidrug resistance markers P-glycoprotein, multidrug resistance protein 1, and lung resistance protein in non-small cell lung cancer: prognostic implications J. Cancer Res. Clin. Oncol. 131 2005 355 363 (Pubitemid 40674620)
3. J.S. Blum, and W.M. Saltzman High loading efficiency and tunable release of plasmid DNA encapsulated in submicron particles fabricated from PLGA conjugated with poly-l-lysine J. Control Release 129 2008 66 72
4. D. Castanotto, and J.J. Rossi The promises and pitfalls of RNA-interference-based therapeutics Nature 457 2009 426 433
5. Y. Chen, J.J. Wu, and L. Huang Nanoparticles targeted with NGR motif deliver c-myc siRNA and doxorubicin for anticancer therapy Mol. Ther. 18 2010 828 834
6. S. Chowdhury, S. Burbridge, and P.G. Harper Chemotherapy for the treatment of hormone-refractory prostate cancer Int. J. Clin. Pract. 61 2007 2064 2070 (Pubitemid 350077400)
7. M.E. Davis, J.E. Zuckerman, C.H. Choi, D. Seligson, A. Tolcher, and C.A. Alabi et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles Nature 464 2010 1067 1070
8. Y.M. Dellian, D. Fukumura, M. Leunig, D.A. Berk, V.P. Torchilin, and R.K. Jain Vascular permeability in a human tumor xenograft: molecular size dependence and cut off size Cancer Res. 55 1995 3752 3756
9. K.H. Downing, and E. Nogales Tubulin and microtubule structure Curr. Opin. Cell Biol. 10 1998 16 22 (Pubitemid 28066117)
10. D.M. Dykxhoorn, C.D. Norvina, and P.A. Sharp Killing the messenger: short RNAs that silence gene expression Nat. Rev. Mol. Cell Biol. 4 2003 457 467 (Pubitemid 36648591)
11. Y. Gao, and X.L. Liu Research progress on siRNA delivery with nonviral carriers Int. J. Nanomed. 6 2011 1017 1025
12. F. Greco, and M.J. Vicent Combination therapy: opportunities and challenges for polymer-drug conjugates as anticancer nanomedicines Adv. Drug Deliv. Rev. 61 2009 1203 1213
13. D.D. Guo, H.S. Moon, R. Arote, J.H. Seo, J.S. Quan, Y.J. Choi, and C.S. Cho Enhanced anticancer effect of conjugated linoleic acid by conjugation with Pluronic F127 on MCF-7 breast cancer cells Cancer Lett. 254 2007 244 254 (Pubitemid 47126692)
14. B. Fulton, and C.M. Spencer Docetaxel: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer Drugs 51 1996 1075 1092
15. S.K. Hobbs, W.L. Monsky, F. Yuan, W.G. Roberts, L. Griffith, V.P. Torchilin, and R.K. Jain Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment Proc. Natl. Acad. Sci. U. S. A 95 1998 4607 4612 (Pubitemid 28207960)
16. A. Jemal, M.J. Thun, L.A. Ries, H.L. Howe, H.K. Weir, and M.M. Center Annual report to the nation on the status of cancer, 1975-2005, featuring trends in lung cancer, tobacco use, and tobacco control J. Natl. Cancer Inst. 100 2008 1672 1694
17. D.H. Kim, and J.J. Rossi Strategies for silencing human disease using RNA interference Nat. Rev. Genet. 8 2007 173 184
18. B. Li, Q. Tang, D. Cheng, C. Qin, F.Y. Xie, and Q. Wei et al. Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in rhesus macaque Nat. Med. 11 2005 944 951 (Pubitemid 41294439)
19. B. Liu, M. Yang, R. Li, Y. Ding, X. Qian, and L. Yu et al. The antitumor effect of novel docetaxel-loaded thermosensitive micelles Eur. J. Pharm. Biopharm. 69 2008 527 534
20. P. Liu, H. Yu, Y. Sun, M. Zhu, and Y. Duan A mPEG-PLGA-b-PLL copolymer carrier for adriamycin and siRNA delivery Biomaterials 33 2012 4403 4412
21. Y. Luo, Y. Ling, W. Guo, J. Pang, W. Liu, Y. Fan, X. Wen, K. Wei, and X. Gao Docetaxel loaded oleic acid-coated hydroxyapatite nanoparticles enhance the docetaxel-induced apoptosis through activation of caspase-2 in androgen independent prostate cancer cells J. Control Rel. 147 2010 278 288
22. S. Meschini, M. Marra, A. Calcabrini, E. Monti, M. Gariboldi, E. Dolfini, and G. Arancia Role of the lung resistance-related protein (LRP) in the drug sensitivity of cultured tumor cells Toxicol. In Vitro 16 2002 389 398 (Pubitemid 34756430)
23. M.L. Miller, and I. Ojima Chemistry and chemical biology of taxane anticancer agents Chem. Rec. 1 2001 195 211 (Pubitemid 33771705)
24. C.V. Pecot, G.A. Calin, R.L. Coleman, G. Lopez-Berestein, and A.K. Sood RNA interference in the clinic: challenges and future directions Nat. Rev. Cancer 11 2011 59 67
25. S.C. Semple, A. Akinc, J.X. Chen, A.P. Sandhu, B.L. Mui, and C.K. Cho et al. Rational design of cationic lipids for siRNA delivery Nat. Biotechnol. 28 2010 172 176
26. T.M. Sun, J.Z. Du, Y.D. Yao, C.Q. Mao, S. Dou, and S.Y. Huang et al. Simultaneous delivery of siRNA and paclitaxel via a two-in-one micelleplex promotes synergistic tumor suppression ACS Nano 5 2011 1483 1494
27. A. Trussardi, G. Poitevin, M.C. Gorisse, M.J. Faroux, H. Bobichon, C. Delvincourt, and J.C. Jardillier Sequential overexpression of LRP and MRP but not P-gp 170 in VP16-selected A549 adenocarcinoma cells Int. J. Oncol. 13 1998 543 548
28. K.A. Whitehead, R. Langer, and D.G. Anderson Knocking down barriers: advances in siRNA delivery Nat. Rev. Drug Discov. 8 2009 129 138
29. Y. Xu, and Z.Z. Szoka Jr. Mechanism of DNA release from cationic liposome/DNAcomplexes used in cell transfection Biochemistry 35 1996 5616 5623 (Pubitemid 26143656)
30. J. Zhao, Y. Mi, and S.S. Feng Targeted co-delivery of docetaxel and siPlk1 by herceptin-conjugated vitamin E TPGS based immunomicelles Biomaterials 34 2013 3411 3421